Search Results
Detection and Targeting of Enzymatic Base Editing Deregulation in Leukemia Stem Cells
Dr. Jamieson is examining the role of two enzymes (APOBEC3 and ADAR1) known to mutate DNA and RNA, and their role in acute myeloid leukemia (AML) and disease relapse, particularly in elderly patients.BURLINGTON STORES RAISES RECORD-BREAKING $5.1 MILLION FOR LLS
Burlington Stores and The Leukemia & Lymphoma Society (LLS) joined forces for the 17th consecutive year to help save lives and bring smiles to those touched by blood cancer. From September 9 through December 1, Burlington’s more than 670 locations nationwide encouraged customers to donate $1 or more at checkout to support LLS’s goal to create a world without blood cancer. This campaign, combined with Burlington’s corporate associate fundraising efforts, raised a record smashing $5.1 million for LLS, helping the organization fund lifesaving research and treatments.
Random Acts of Light Day Serves As an Annual Reminder of Our Goal to Create a World without Blood Cancers
The Leukemia & Lymphoma Society (LLS) is out to prove the benefit of everyday kindness, on the third annual National Random Acts of Light Day, set for June 13. In conjunction with LLS’s Light The Night campaign, Random Acts of Light aims to create awareness and educate the public about the critical need to fund research to find cures for blood cancer patients, and ensure they have access to lifesaving treatments.
Blood Cancer Discovery Helping Cardiovascular Patients
An exciting scientific discovery, originally found through blood cancer research, makes headlines when researchers uncover new implications for cardiovascular disease.
The Leukemia & Lymphoma Society (LLS) is laser-focused on finding cures for patients with blood cancers. But did you know that the research we support has far greater reach? In fact, many of the therapeutic advances that occurred first in blood cancer are now helping patients with other types of cancers and serious diseases.
Mechlorethamine
Mechlorethamine is FDA approved to treat people who have Hodgkin lymphoma, chronic myeloid leukemia, chronic lymphocytic leukemia, polycythemia vera and mycosis fungoides.
Ofatumumab
Ofatumumab is FDA approved
- For the treatment of patients who have chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab.
- For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL.
- In combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL), for whom fludarabine-based therapy is considered inappropriate.
Random Acts of Light: Burlington and LLS Surprise Cancer Patient after Hurricane Harvey
Burlington Stores and The Leukemia & Lymphoma Society (LLS) surprised Mateo Rubio – a three-year-old boy with acute lymphoblastic leukemia (ALL), and his mother, Ana Torres – each with a gift card to Burlington, to help bring light to the darkness of cancer and to help purchase new belongings following the destruction of their home in Hurricane Harvey.
EXPANDING FEDERAL RESOURCES FOR BLOOD CANCER RESEARCH
Learn how The Leukemia & Lymphoma Society (LLS) played a key role in restoring research for all blood cancers as a priority funding area for 2018.
When we think of the federal government’s investments in medical research, we almost always think of the National Institutes of Health (NIH), our nation’s medical research agency. For more than a century, NIH has paved the way for scientific breakthroughs that are helping people live longer, healthier lives.
HIGH SCHOOL STUDENTS 'TEST' THE LIMITS OF PHILANTHROPY
For the second year in a row, high school students across the country are redefining what it means to be philanthropic in today’s youth culture. Through The Leukemia & Lymphoma Society’s (LLS) newest innovation in fundraising, Students of the Year, more than 600 motivated high school students raised significant funds for LLS’s cutting-edge cancer research and patient services.
Reflections from the #ASH19 Meeting
As the 61st Annual ASH (American Society of Hematology) Meeting and Exhibition winds down here in Orlando, here are some thoughts on where things stand in the world of blood cancers.
Bringing the Patient Voice into Drug Development
Wanting to make sure the patient voice is heard when it comes to the development of new therapies, The Leukemia & Lymphoma Society (LLS) recently brought a delegation to Washington D.C. to share personal experiences with the U.S. Food & Drug Administration (FDA). Plans for a research study to learn what patients and caregivers are looking for in new treatments were also presented.
Topotecan
Topotecan is an FDA-approved cancer drug that is used to treat people who have certain types of cancer including acute myeloid leukemia and acute lymphoblastic leukemia. This drug may cause a temporary loss of hair in some people. After treatment with topotecan has ended, normal hair growth should return.
Doxorubicin
Doxorubicin is FDA approved to treat people who have some kinds of blood cancer, including acute lymphoblastic leukemia, acute myeloblastic leukemia, and Hodgkin and non-Hodgkin lymphoma.
Defining and Redefining a Blood Cancer Diagnosis
Science historian June Goodfield wrote, “Cancer begins and ends with people.”
This Blood Cancer Awareness Month, it’s important to know that The Leukemia & Lymphoma Society (LLS) is on a mission to cure blood cancers and improve quality of life for the nearly 1.7 million people in the U.S. living with or in remission from blood cancer.
LLS is all about people—an organization full of people who are united in the urgent effort to help every person impacted by blood cancer.
LLS and Burlington Stores: Spreading Smiles Across the Country
For 16 years, Burlington Stores has partnered with The Leukemia & Lymphoma Society (LLS), funding research and lifesaving treatments. Together, they have saved lives and helped bring smiles to those touched by blood cancers, with more than $32 million raised to date. However, with nearly 1.3 million people in the U.S. living with or in remission from blood cancers, there is still more work to be done.
A Cancer Survivor Gives Back
When I meet newly diagnosed cancer patients and their caregivers, a familiar look greets me. I have seen this look countless times. In waiting rooms, during a weekly support lunch for patients and caregivers, and on my own mother’s face.
It is a look of fear, confusion and doubt. It is a look that expresses the need for survival at all costs, yet without any assurance of success. It is a look that I can still see when I look in the mirror.
That look is often replaced almost immediately after I say: “Hi, my name is Ron. I am a leukemia and stem-cell transplant survivor.”
Clinical Trials: Why They Matter and How to Make Them More Accessible
Cancer treatments can be lifesaving. As an organization, The Leukemia & Lymphoma Society (LLS) has invested more than $1.7 billion in blood cancer research since its inception in 1949—all with the hope that this research leads to scientific breakthroughs that improve and save lives.
But to make sure this research leads to safe and innovative treatments, we have to thoroughly test it.
A Special Delivery for Mom with Cancer
On April 8, 2016, I was diagnosed with acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia (AML). I was 23 weeks pregnant. For almost five years, my husband, Allan, and I battled unexplained infertility. After three failed fertility treatments, we finally found ourselves pregnant the “au natural” way!
What’s Next in Blood Cancer: Looking Ahead to 2023
The most important blood cancer scientific meeting, the American Society of Hematology (ASH), is held every December.
Interrogation of glutathione biology in relapsed acute myeloid leukemia stem cells
Acute myeloid leukemia (AML) is a devastating blood cancer. Most AML patients will initially respond to standard therapy; however, for many patients the disease recurs resulting in patient death. Consequently, there is an urgent need to develop new therapeutic strategies for relapsed AML patients. The objective of our proposal is to understand and target properties specific to relapsed AML cells with the overall goal of improving relapsed AML patient outcomes.Understanding Mutations to Treat MDS
Benjamin Ebert is researching what genetic mutations cause myelodysplastic syndromes (MDS), a group of disorders in which the bone marrow fails to produce sufficient blood cells, and how that information can be used to determine prognosis and therapy. MDS frequently progresses to an acute leukemia.
Improving the outcomes of young Black adults diagnosed with acute myeloid leukemia
Young Black patients diagnosed with acute myeloid leukemia (AML) have significantly shorter survival compared to White patients. To comprehensively assess genetic, genomic and biologic contributors to the race-associated survival disparity, we propose a complementary approach that addresses major knowledge gaps in our current understanding of AML biology in Black patients, including the overdue characterization of the Black AML genome and subsequent delineation of biologic response to treatment.BRAF inhibition as an alternative to chemotherapy in the treatment strategy of hairy cell leukemia
Hairy cell leukemia (HCL) is very sensitive to chemotherapy, whose toxicity to the bone marrow and the immune system is however concerning. We have established vemurafenib plus rituximab as a very effective chemotherapy-free regimen in relapsed/refractory HCL (NEJM, in press). Here, we will test it in a clinical trial against a chemotherapy-based standard of care represented by cladribine plus rituximab, aiming at lower toxicity and similar efficacy.
Finding Support in Community: Walgreens and LLS Show Up for Blood Cancer Patients
We all need a helping hand sometimes.
Add on a cancer diagnosis and the everyday suddenly feels... different. In many ways, harder.